乳果糖联合或不联合远程太极预防肝硬化患者跌倒的SMART试验
这项24周两阶段SMART试验纳入230例无既往显性肝性脑病的肝硬化门脉高压成人,第一阶段随机接受乳果糖或强化常规照护,第二阶段随机接受远程太极或强化常规照护。乳果糖降低跌倒及跌倒相关伤害,序贯乳果糖后远程太极优于强化常规照护。
要点
- 乳果糖降低肝硬化患者伤害性跌倒和非伤害性跌倒风险。
- 序贯乳果糖后远程太极较强化常规照护降低主要复合结局风险。
- 乳果糖未增加死亡/移植或不良事件风险。
核心结论
- 在无既往显性肝性脑病的肝硬化门脉高压患者中,乳果糖减少跌倒及跌倒相关伤害。
- 序贯乳果糖后远程太极也优于强化常规照护。
研究设计与样本
- 24周两阶段序贯多 assignment 随机对照试验(SMART),在密歇根、宾夕法尼亚和德克萨斯4个中心纳入230例肝硬化门脉高压成人。
- 第一阶段(1-12周)随机接受乳果糖或强化常规照护(营养和跌倒预防教育)。
- 第二阶段(13-24周)随机接受远程太极或强化常规照护(运动教育)。
- 采用意向性治疗(ITT)胜率比(WR)分析。
主要发现
- 乳果糖后远程太极与强化常规照护相比,伤害性跌倒为4% vs. 12%,非伤害性跌倒为19% vs. 32%,显性肝性脑病为2% vs. 0%,死亡/移植为0% vs. 0%。
- 乳果糖使用者与非使用者相比,伤害性跌倒为3.5% vs. 8.5%,非伤害性跌倒为15.0% vs. 26.5%,显性肝性脑病为1.8% vs. 2.6%,死亡/移植或不良事件无差异,WR 2.3,95% CI(1.3-4.0)。
- 序贯乳果糖/远程太极与常规照护相比降低主要结局风险,WR 2.7,95% CI(1.3-5.5)。
临床怎么用
- 对于无既往显性肝性脑病的肝硬化门脉高压患者,可考虑使用乳果糖以降低跌倒及跌倒相关伤害风险。
- 序贯乳果糖后远程太极可作为强化常规照护的替代方案以进一步降低主要复合结局风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Falls are common and morbid for patients with cirrhosis, and patients have identified reducing fall risk as an unmet need and care priority. APPROACH AND RESULTS: This is a 24-week two-stage Sequential, Multiple Assignment Randomized Trial (SMART) at 4 centers in Michigan, Pennsylvania, and Texas enrolling 230 adults with cirrhosis and portal hypertension without prior overt hepatic encephalopathy (HE). There were 2 stages. In stage 1 (weeks 1-12), participants were randomized to lactulose or enhanced usual care (education on nutrition and fall prevention). In stage 2 (weeks 13-24), participants were randomized to TeleTai-Chi or enhanced usual care (exercise education). We evaluated the effectiveness of lactulose with or without TeleTai-Chi. The primary outcome was a hierarchical composite of death or transplantation, injurious falls, incident HE, and non-injurious falls. We used an intention-to-treat (ITT) win ratio (WR). Lactulose followed by TeleTai-Chi, compared with enhanced usual care, reduced injurious falls (4% vs. 12%) and non-injurious falls (19% vs. 32%), with no differences in overt HE (2% vs. 0%) or death/transplantation (0% vs. 0%). Compared with non-users, lactulose users experienced fewer injurious falls (3.5% vs. 8.5%), non-injurious falls (15.0% vs. 26.5%), and overt HE (1.8% vs. 2.6%), with no difference in death/transplantation or adverse events, resulting in a WR 2.3, 95% CI (1.3-4.0). Sequential lactulose/TeleTai-Chi reduced the risk of the primary outcome compared with usual care (WR 2.7, 95% CI (1.3-5.5). CONCLUSION: In patients with cirrhosis and portal hypertension without prior overt HE, lactulose reduced falls and fall-related harms. Sequential lactulose followed by TeleTai-Chi was also superior to enhanced usual care.
引用
- Tapper EB, Asrani S, Weinberg E, et al. Lactulose with or without TeleTai-Chi for the prevention of falls: A sequential multiple assignment randomized controlled trial (LiveSMART). Hepatology. 2026. PMID: 42752551. doi:10.1097/HEP.0000000000001869
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。